Sign in
Active, not recruitingPhase 2

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Key facts

Who runs it
GlaxoSmithKline
Where
Austin, Binghamton, Birmingham, Charleston, Charlotte, Endwell, Galveston, Grand Island, Gresham, Haughton, Kingsport, Layton, Lincoln, Macon, Miami, Missoula, Nicholasville, Omaha, Tucson, Valparaiso, Ventura, and Washington D.C., United StatesSee the 22 sitesAlso in 1 other country, 6 sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
305 people enrolled
Started
18 Nov 2021
Expected to end
10 Mar 2027
Type of study
Interventional, 2 groups
Treatments tested
  • MenABCWY vaccine
  • Placebo
Record updated
28 September 2026

Who can take part

Age
11 years to 14 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Participants or/and participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
  • Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure
  • Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure
  • A male or female between, and including, 11 and 14 years of age (i.e. 14 years + 364 days) at the time of the first vaccination
  • Healthy participants as established by medical history, physical examination and clinical judgment of the investigator before entering into the study
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral-salpingectomy or bilateral ovariectomy
  • Female participants of childbearing potential may be enrolled in the study, if the participant:; has practiced adequate contraception for 30 days prior to first vaccination, and; has a negative pregnancy test* on the day of vaccination, and; has agreed to follow adequate contraception for 30 days before each of the 2 subsequent vaccinations and for 30 days after each vaccination * Urine samples for pregnancy testing will be collected from female participants of childbearing potential at Visit 1, Visit 3 and Visit 5 prior to the vaccination

Who cannot take part

  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Abnormal function or modification of the immune system resulting from:; Autoimmune disorders or immunodeficiency syndromes; Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination. This will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed; Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination; Administration of long-acting immune-modifying drugs at any time during the study period
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study; Prior/Concomitant therapy
  • Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study vaccine(s)/product(s) during the period starting 30 days before the first dose of study vaccine(s)/product(s) (Day -29 to Day 1), or planned use during the study period
  • Previous vaccination with any meningococcal (MenB or MenACWY) vaccine at any time prior to informed consent/ assent (as applicable) with the exception of meningococcal C (conjugated or polysaccharide) vaccination, if the last dose of MenC was received at ≤24 months of age
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of study vaccine/product or planned administration before the next blood sampling visit
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine/product dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed; Prior/Concurrent clinical study experience
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device); Other exclusions
  • Medical conditions
  • Progressive, unstable or uncontrolled clinical conditions
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
  • Any neuroinflammatory, congenital neurological conditions, encephalopathies, seizures. History of febrile convulsions should not lead to exclusion
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s)/product(s); Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study
  • History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment
  • Child in care
  • Pregnant or lactating female
  • Female planning to become pregnant / planning to discontinue contraceptive precautions during the windows reported in the inclusion criterion
  • Any study personnel or immediate dependants, family, or household members

Where in United States

Also in 1 other country, 6 sites

  • Austin, TexasHospital not named in the registry
  • Binghamton, New YorkHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Charlotte, North CarolinaHospital not named in the registry
  • Endwell, New YorkHospital not named in the registry
  • Galveston, TexasHospital not named in the registry
  • Grand Island, NebraskaHospital not named in the registry
  • Gresham, OregonHospital not named in the registry
  • Haughton, LouisianaHospital not named in the registry
  • Kingsport, TennesseeHospital not named in the registry
  • Layton, UtahHospital not named in the registry
  • Lincoln, NebraskaHospital not named in the registry
  • Macon, GeorgiaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Missoula, MontanaHospital not named in the registry
  • Nicholasville, KentuckyHospital not named in the registry
  • Omaha, NebraskaHospital not named in the registry
  • Tucson, ArizonaHospital not named in the registry
  • Valparaiso, IndianaHospital not named in the registry
  • Ventura, CaliforniaHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.

The 2 groups in the trial

  • ABCWY-24 GroupTreatment being tested

    Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.

    Treatment: MenABCWY vaccine and Placebo

  • ABCWY-48 GroupTreatment being tested

    Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.

    Treatment: MenABCWY vaccine and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Record updated
28 September 2026